{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:30:25Z","timestamp":1795102225955,"version":"4.10.3"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua City Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vaccine.2025.127964","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:43:31Z","timestamp":1762555411000},"page":"127964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B"],"prefix":"10.1016","volume":"68","author":[{"given":"Geng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhedi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127964_bb0005","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2018.1450121","article-title":"Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: prevalence of strains potentially covered by the presently available meningococcal B vaccines","volume":"14","author":"Terranova","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127964_bb0010","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0015","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s40121-023-00836-8","article-title":"Meningococcal B immunisation in adults and potential broader immunisation strategies: a narrative review","volume":"12","author":"Kassianos","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2025.127964_bb0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2025.127964_bb0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2025.127964_bb0030","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127964_bb0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/microorganisms9050900","article-title":"The impact and burden of neurological sequelae following bacterial meningitis: a narrative review","volume":"9","author":"Schiess","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.127964_bb0040","series-title":"Meningococcal disease: public health burden and control. World health statistics quarterly Rapport trimestriel de statistiques sanitaires mondiales","first-page":"170","volume":"50","author":"Tikhomirov","year":"1997"},{"key":"10.1016\/j.vaccine.2025.127964_bb0045","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1016\/j.vaccine.2022.06.038","article-title":"Vaccines against Neisseria meningitidis serogroup B strains \u2013 what does genomics reveal on the Portuguese strain\u2019s coverage","volume":"40","author":"Bettencourt","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0050","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2357924","article-title":"4CMenB journey to the 10-year anniversary and beyond","volume":"20","author":"Abitbol","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127964_bb0055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406332121","article-title":"Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire","volume":"121","author":"Abt","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127964_bb0060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jcpt.13083","article-title":"A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp","volume":"45","author":"Burman","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"138","key":"10.1016\/j.vaccine.2025.127964_bb0065","first-page":"4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"1987","author":"Finne","year":"1950","journal-title":"J Immunol (Baltimore, Md)"},{"key":"10.1016\/j.vaccine.2025.127964_bb0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127964_bb0075","first-page":"ftx033","article-title":"Novel approaches to Neisseria meningitidis vaccine design","volume":"75","author":"Christodoulides","year":"2017","journal-title":"Pathogens Dis"},{"key":"10.1016\/j.vaccine.2025.127964_bb0080","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","author":"Weynants Vincent","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127964_bb0085","doi-asserted-by":"crossref","first-page":"1473064","DOI":"10.3389\/fimmu.2024.1473064","article-title":"Characterisation and immunogenicity of Neisseria cinerea outer membrane vesicles displaying NadA, NHBA and fHbp from Neisseria meningitidis serogroup B","volume":"15","author":"Manoharan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127964_bb0090","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127964_bb0095","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2025.127964_bb0100","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB\u2122: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0105","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127964_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2206433","article-title":"Effectiveness of a meningococcal group B vaccine (4CMenB) in children","volume":"388","author":"Castilla","year":"2023","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2025.127964_bb0115","first-page":"1","article-title":"Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia region, 2014\u201319","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127964_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127964_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0316184","article-title":"A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections","volume":"20","author":"Metelmann","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.127964_bb0130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1377\/hlthaff.2011.0295","article-title":"Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa","volume":"30","author":"Bishai","year":"2011","journal-title":"Health Aff"},{"key":"10.1016\/j.vaccine.2025.127964_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2206433","article-title":"Effectiveness of a meningococcal group B vaccine (4CMenB) in children","volume":"388","author":"Castilla","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127964_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2025.127964_bb0145","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.3390\/ijms252313139","article-title":"Current Progress in the development of mRNA vaccines against bacterial infections","volume":"25","author":"Khlebnikova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2025.127964_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.127964_bb0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson Mark","year":"2021","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2025.127964_bb0160","article-title":"FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system","volume":"2","author":"Pawlowski","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/M21-3256","article-title":"COVID-19 vaccination effectiveness against infection or death in a National U.S. health care system","volume":"175","author":"Ioannou","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2025.127964_bb0170","first-page":"9","article-title":"An update on self-amplifying mRNA vaccine development","author":"Blakney","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127964_bb0175","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ymthe.2022.04.014","article-title":"A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through;cell-mediated immunity","volume":"30","author":"McCafferty","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2025.127964_bb0180","first-page":"44","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","author":"Pollock","year":"2022","journal-title":"eClinicalMed"},{"key":"10.1016\/j.vaccine.2025.127964_bb0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-021-00420-6","article-title":"Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza","volume":"6","author":"Chivukula","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127964_bb0190","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1042\/BCJ20210015","article-title":"Evaluation of artificial signal peptides for secretion of two lysosomal enzymes in CHO cells","volume":"478","author":"Cheng","year":"2021","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2025.127964_bb0195","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/1947-2714.100998","article-title":"Western blot: technique, theory, and trouble shooting","volume":"4","author":"Mahmood","year":"2012","journal-title":"North Am J Med Sci"},{"key":"10.1016\/j.vaccine.2025.127964_bb0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1538\/expanim.59.47","article-title":"Indirect ELISA and Indirect immunofluorescent antibody assay for detecting the antibody against murine norovirus S7 in mice","volume":"59","author":"Kitagawa","year":"2010","journal-title":"Exp Anim"},{"key":"10.1016\/j.vaccine.2025.127964_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100351","article-title":"Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry","volume":"2","author":"Skordos","year":"2021","journal-title":"STAR Protocols"},{"key":"10.1016\/j.vaccine.2025.127964_bb0210","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2302","article-title":"ELISPOT assay to measure peptide-specific IFN-\u03b3 production","volume":"7","author":"Wykes","year":"2017","journal-title":"Bio-protocol"},{"key":"10.1016\/j.vaccine.2025.127964_bb0215","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0220","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0225","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/14760584.2023.2244596","article-title":"Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness","volume":"22","author":"Borrow","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127964_bb0230","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1073\/pnas.0909910107","article-title":"Translation efficiency is determined by both codon bias and folding energy","volume":"107","author":"Tuller","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127964_bb0235","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01693-19","article-title":"The glycoprotein of the live-attenuated Junin virus vaccine strain induces endoplasmic reticulum stress and forms aggregates prior to degradation in the lysosome","volume":"94","author":"Manning","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127964_bb0240","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","article-title":"Influence of protein fold stability on immunogenicity and its implications for vaccine design","volume":"16","author":"Scheiblhofer","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127964_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1673","article-title":"Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial","volume":"11","author":"Kallas","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127964_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28326","article-title":"Assessment of the immune interference effects of multivalent vaccine for influenza epidemic strain in 2022-2023 and evaluation of its efficacy","volume":"10","author":"Ga","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.vaccine.2025.127964_bb0255","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/vaccines12030318","article-title":"Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19","volume":"12","author":"Silva-Pilipich","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127964_bb0260","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127964_bb0265","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2025.127964_bb0270","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1248\/bpb.b25-00155","article-title":"Evaluating signal peptide efficiency for extracellular protein secretion for mRNA vaccine design","volume":"48","author":"Sato","year":"2025","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.vaccine.2025.127964_bb0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T cells against conserved HIV-1 regions by Mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Molecular Ther Meth Clin Dev"},{"key":"10.1016\/j.vaccine.2025.127964_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126883","article-title":"Sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models","volume":"51","author":"Chang","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127964_bb0285","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.1546329","article-title":"HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation","volume":"255","author":"Henderson","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127964_bb0290","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s42003-021-01965-x","article-title":"Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation","volume":"4","author":"Liew","year":"2021","journal-title":"Commun Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127964_bb0295","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/v16030484","article-title":"A cocktail of lipid nanoparticle-mRNA vaccines broaden immune responses against \u03b2-coronaviruses in a murine model","volume":"16","author":"Zhang","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127964_bb0300","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2204151","article-title":"Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge","volume":"12","author":"Zeng","year":"2023","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127964_bb0305","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/vaccines9090964","article-title":"Simultaneous immunization with multiple diverse immunogens alters development of antigen-specific antibody-mediated immunity","volume":"9","author":"Pilewski","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127964_bb0310","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127964_bb0315","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/v17040566","article-title":"Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development","volume":"17","author":"Vallet","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127964_bb0320","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.sbi.2008.07.001","article-title":"Overcoming the challenges of membrane protein crystallography","volume":"18","author":"Carpenter","year":"2008","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127964_bb0325","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/biom15010084","article-title":"Lipid antigens: revealing the hidden players in adaptive immune responses","volume":"15","author":"Eskandari","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.vaccine.2025.127964_bb0330","doi-asserted-by":"crossref","first-page":"91","DOI":"10.7774\/cevr.2024.13.2.91","article-title":"A narrative review of genomic characteristics, serotype, immunogenicity, and vaccine development of Streptococcus pneumoniae capsular polysaccharide","volume":"13","author":"Sari","year":"2024","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2025.127964_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/QCO.0000000000000264","article-title":"Bordetella pertussis: new concepts in pathogenesis and treatment","volume":"29","author":"Carbonetti","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127964_bb0340","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s43556-024-00243-6","article-title":"Tuberculosis vaccines and therapeutic drug: challenges and future directions","volume":"6","author":"An","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.vaccine.2025.127964_bb0345","doi-asserted-by":"crossref","first-page":"2396220","DOI":"10.1080\/21645515.2024.2396220","article-title":"Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: a mini review","volume":"20","author":"Palmieri","year":"2024","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:27:14Z","timestamp":1781663234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25012629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":69,"alternative-id":["S0264410X25012629"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127964","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127964"}}